The effect of bifid triple viable on immune function of patients with ulcerative colitis - PubMed (original) (raw)

The effect of bifid triple viable on immune function of patients with ulcerative colitis

Guohua Li et al. Gastroenterol Res Pract. 2012.

Abstract

Objective. To study effect and its mechanism of Bifid Triple Viable for initially treating ulcerative colitis with 5-aminosalicylic acid. Methods. 82 patients, who were firstly diagnosed as ulcerative colitis, were randomized into experiment group (41 cases, treated with Bifid Triple Viable and Etiasa) and control group (41 cases, treated with Etiasa). The clinic symptom score, colon mucosa inflammation score, and some immune indices were detected and compared between two groups before and two months after treatment. Results. Two months after treatment, the clinical symptom score, colon mucosa inflammation score, and IL-1β expression in colon mucosa decreased significantly (P < 0.01), and IL-10 and IgA expressions in colon mucosa increased significantly (P < 0.01). Those differences were more marked in experiment group than control group (P < 0.05). However, peripheral blood T cell subgroup, immunoglobulins, and complements had no significant difference between two groups two months after treatment, but the ratio of peripheral blood CD4+ T cell to CD8+ T cell in experiment group increased more than that in control group (P < 0.05). Conclusion. Bifid Triple Viable contributed to Etiasa to treat ulcerative colitis in inducing remission period, which was perhaps related to affecting the patient's immune function.

PubMed Disclaimer

Figures

Figure 1

Figure 1

EG stands for experiment group; CG stands for control group; BT stands for “before treatment”. AT stands for “after treatment”. Ratio stands for the tenfold ratio of CD4+T cells to CD8+ T cells. There was no significant difference regarding the average values of T-cell subgroup between two groups before treatment and two months after treatment (P > 0.05). However, the ratio of CD4+ T cell to CD8+ T cell in experiment group two months after treatment increased more than that in control group (P < 0.05).

Figure 2

Figure 2

EG stands for experiment group; CG stands for control group; BT stands for “before treatment”. AT stands for “after treatment”. The average number of positive immunoreactivity particles for IgA, IL-1_β_, or IL-10 in colon mucosa was no significant difference before treatment between two groups. Two months after treatment, the average number of positive particles for IgA and IL-10 in colon mucosa in each group increased significantly (P < 0.01). Moreover, the average number of positive particles for IgA and IL-10 in experiment group was more than that in control group (P < 0.01). However, average number of positive particles of IL-1_β_ was opposite to that of IgA and IL-10 (P < 0.05).

Figure 3

Figure 3

No positive particle (1 × 100).

Figure 4

Figure 4

Positive particle for anti-IL-10 (1 × 40).

Figure 5

Figure 5

Positive particle for anti-IgA (1 × 100).

Figure 6

Figure 6

Positive particle for anti-IL-1_β_ (1 × 40).

Similar articles

Cited by

References

    1. Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Current Opinion in Gastroenterology. 2005;21(4):408–413. - PubMed
    1. Hajj Hussein IA, Tohme R, Barada K, et al. Inflammatory bowel disease in rats: bacterial and chemical interaction. World Journal of Gastroenterology. 2008;14(25):4028–4039. - PMC - PubMed
    1. Trivedi NN, Caughey GH. Mast cell peptidases: chameleons of innate immunity and host defense. American Journal of Respiratory Cell and Molecular Biology. 2010;42(3):257–267. - PMC - PubMed
    1. Garrett WS, Gallini CA, Yatsunenko T, et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host and Microbe. 2010;8(3):292–300. - PMC - PubMed
    1. Png CW, Lindén SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. American Journal of Gastroenterology. 2010;105(11):2420–2428. - PubMed

LinkOut - more resources